Research Open access Published: 12 October 2023

Comparing the CFIR-ERIC matching tool recommendations to real-world strategy effectiveness data: a mixed-methods study in the Veterans Health Administration

Vera Yakovchenko, Carolyn Lamorte, Matthew J. Chinman, David E. Goodrich, Sandra Gibson, Angela Park,

Jasmohan S. Bajaj, Heather McCurdy, Timothy R. Morgan & Shari S. Rogal 🖾

*Implementation Science* **18**, Article number: 49 (2023) <u>Cite this article</u>

2242 Accesses 3 Altmetric Metrics

Shari Rogal MD, MPH

VA Pittsburgh Center for Health Equity Research and Promotion (CHERP)

April 4, 2022

Implementation Research Group Cyber-Seminar

1

https://implementationscience.biomedcentral.com/articles/10.1186/s13012-023-01307-x

# Outline



Implementation strategies



**CFIR-ERIC** matching tool




Assessing CFIR-ERIC matching tool in real world




**Future directions** 

Strategy Taxonomy: Expert Recommendations for Implementing Change (ERIC)



Powell et al (2015) Imp Sci


### We can track implementation strategy selection



Strategies in Order of Presentation on Survey


Rogal et al. (2017) Implementation Science

### We can assess the success of strategies over time



Waltz et al (2015) Implementation Science Rogal et al. (2019) Implementation Science

### We can identify effective combinations




participants in HCV care


			Path 1	Path 2	Path 3	Path 4	Path 5	Covered by
	CASE	Ουτ	S24	S34 S45	S22 S61	S56 S71	S18 S47 S70	Solution
_	SITE 21			• •	022 001	000 0/1	• • •	•
	SITE 01		•			• •	• • •	•
	SITE 68 SITE 24		•					
	SITE 24 SITE 57				•••			
	SITE 02			• •			• • •	•
6	SITE 16 SITE 04		•		•••			•
4	SITE 59						• • •	•
z	SITE 26 SITE 03		•	•••				•
ts	SITE 03 SITE 34							•
tar	SITE 39						• • •	•
t s	SITE 41 SITE 47		$\vdash$					L .
en	SITE 72			• •	• •	• •	• • •	•
Ē	SITE 13 SITE 33	1				• •		•
eat	SITE 23		•					•
Ě	SITE 45						• • •	•
>	SITE 27 SITE 71		$\vdash$	•••	$ \rightarrow $			
오	SITE 60		•	• •				•
Higher HCV Treatment Starts (N=40)	SITE 40 SITE 77	_	•	• •	•••	•••		
Ē	SITE 30				• •			•
Ξ	SITE 32 SITE 17			• •			• • •	
÷	SITE 55		•	• •	• •			•
Sites with	SITE 80 SITE 10							•
S	SITE 10 SITE 79		•					
Site	SITE 76				• •		• • •	•
•,	SITE 15 SITE 54		•	• •	•••			•
	SITE 56				• •			•
	SITE 14 SITE 44		•	• •		•••	• • •	•
	SITE 63							
	SITE 78							
							• • •	•
	SITE 58							
	SITE 20							
	SITE 20 SITE 67 SITE 50							
	SITE 20 SITE 67 SITE 50 SITE 25							
	SITE 20 SITE 67 SITE 50 SITE 25 SITE 12 SITE 19							
40)	SITE 20 SITE 67 SITE 50 SITE 25 SITE 12 SITE 19 SITE 52							
N=40)	SITE 20 SITE 67 SITE 50 SITE 25 SITE 12 SITE 19 SITE 52 SITE 64 SITE 70							
s (N=40)	SITE 20 SITE 67 SITE 50 SITE 25 SITE 12 SITE 19 SITE 52 SITE 64 SITE 70 SITE 61							
arts (N=40)	SITE 20 SITE 67 SITE 50 SITE 25 SITE 12 SITE 19 SITE 52 SITE 64 SITE 61 SITE 61 SITE 49							
Starts (N=40)	SITE 20 SITE 67 SITE 50 SITE 25 SITE 12 SITE 19 SITE 52 SITE 64 SITE 70 SITE 61 SITE 49 SITE 49 SITE 43 SITE 09							
nt Starts (N=40)	SITE 20   SITE 67   SITE 50   SITE 12   SITE 12   SITE 150   SITE 12   SITE 61   SITE 43   SITE 43   SITE 09   SITE 75							
nent Starts (N=40)	SITE 20   SITE 67   SITE 50   SITE 52   SITE 12   SITE 15   SITE 52   SITE 64   SITE 70   SITE 43   SITE 43   SITE 69   SITE 69   SITE 69   SITE 69   SITE 74							
atment Starts (N=40)	SITE 20   SITE 67   SITE 50   SITE 52   SITE 12   SITE 12   SITE 12   SITE 61   SITE 61   SITE 49   SITE 43   SITE 70   SITE 61   SITE 61   SITE 75   SITE 69   SITE 71							
reatment Starts (N=40)	SITE 20   SITE 67   SITE 50   SITE 12   SITE 12   SITE 12   SITE 15   SITE 16   SITE 61   SITE 61   SITE 61   SITE 61   SITE 63   SITE 64   SITE 75   SITE 75   SITE 75   SITE 74   SITE 74   SITE 74   SITE 11   SITE 31   SITE 42							
V Treatment Starts (N=40)	SITE 20   SITE 50   SITE 50   SITE 50   SITE 12   SITE 15   SITE 16   SITE 61   SITE 43   SITE 70   SITE 61   SITE 63   SITE 64   SITE 63   SITE 64   SITE 64   SITE 61   SITE 63   SITE 64   SITE 74   SITE 74   SITE 74   SITE 74   SITE 74   SITE 75   SITE 62   SITE 74   SITE 75   SITE 74							
HCV Treatment Starts (N=40)	SITE 20   SITE 50   SITE 50   SITE 50   SITE 12   SITE 12   SITE 50   SITE 51   SITE 52   SITE 51   SITE 52   SITE 53   SITE 64   SITE 64   SITE 64   SITE 63   SITE 64   SITE 64   SITE 63   SITE 64   SITE 74   SITE 74   SITE 63   SITE 64   SITE 65							
rr HCV Treatment Starts (N=40)	SITE 20   SITE 50   SITE 50   SITE 50   SITE 51   SITE 52   SITE 12   SITE 19   SITE 50   SITE 50   SITE 61   SITE 63   SITE 64   SITE 63   SITE 64   SITE 63   SITE 64   SITE 64   SITE 63   SITE 64   SITE 64   SITE 63   SITE 64   SITE 64 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>							
wer HCV Treatment Starts (N=40)	SITE 20   SITE 67   SITE 50   SITE 22   SITE 12   SITE 61   SITE 61   SITE 63   SITE 64   SITE 74   SITE 74   SITE 74   SITE 74   SITE 74   SITE 60   SITE 66   SITE 63   SITE 64   SITE 63   SITE 64   SITE 74   SITE 74   SITE 74   SITE 64   SITE 65   SITE 67   SITE 61   SITE 62   SITE 22   SITE 24							
Lower HCV Treatment Starts (N=40)	SITE 20   SITE 67   SITE 50   SITE 52   SITE 12   SITE 14   SITE 20   SITE 20   SITE 23   SITE 24   SITE 24   SITE 24   SITE 24							
th Lower HCV Treatment Starts (N=40)	SITE 20   SITE 67   SITE 50   SITE 25   SITE 25   SITE 12   SITE 14							
with Lower HCV Treatment Starts (N=40)	SITE 20   SITE 67   SITE 50   SITE 25   SITE 12   SITE 13   SITE 14   SITE 24   SITE 25   SITE 24   SITE 25   SITE 24   SITE 25   SITE 25   SITE 25   SITE 25   SITE 25   SITE 26   SITE 26 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>							
s with Lower HCV Treatment Starts (N=40)	SITE 20   SITE 20   SITE 20   SITE 20   SITE 20   SITE 20   SITE 21   SITE 22   SITE 20							
ites with Lower HCV Treatment Starts (N=40)	SITE 20   SITE 20   SITE 20   SITE 20   SITE 20   SITE 20   SITE 21   SITE 22   SITE 20   SITE 20 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>							
Sites with Lower HCV Treatment Starts (N=40)	SITE 20 SITE 20 SIT							
Sites with Lower HCV Treatment Starts (N=40)	SITE 67   SITE 67   SITE 20   SITE 50   SITE 50   SITE 12   SITE 12   SITE 12   SITE 50   SITE 50   SITE 52   SITE 50   SITE 60   SITE 60   SITE 70   SITE 60   SITE 70   SITE 71   SITE 72   SITE 74   SITE 74   SITE 74   SITE 74   SITE 75   SITE 74   SITE 74   SITE 74   SITE 75   SITE 75 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>							
Sites with Lower HCV Treatment Starts (N=40)	SITE 20   SITE 21   SITE 21   SITE 22   SITE 22   SITE 20							
Sites with Lower HCV Treatment Starts (N=40)	SITE 60   SITE 61   SITE 50   SITE 50   SITE 50   SITE 12   SITE 12   SITE 12   SITE 12   SITE 12   SITE 12   SITE 43   SITE 44   SITE 43   SITE 75   SITE 74   SITE 61   SITE 63   SITE 64   SITE 73   SITE 64   SITE 65   SITE 66   SITE 67   SITE 68   SITE 68   SITE 73   SITE 73   SITE 74   SITE 73   SITE 74   SITE 73   SITE 73   SITE 74   SITE 74   SITE 73   SITE 74   SITE 74   SITE 73   SITE 74 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>							
Sites with Lower HCV Treatment Starts (N=40)	SITE 20   SITE 21   SITE 21   SITE 22   SITE 22   SITE 20							

Yakovchenko et al. (2020) Medical Care

# We can prescribe successful strategies



How do we do this quickly and efficiently?



# CFIR

- Damschroder et al. (2009) Imp Sci
- Damschroder et al. (2022) Imp Sci

# CFIR-ERIC Implementation Strategy Matching Tool

Matches implementation barriers and facilitators, identified using the CFIR with expertrecommended implementation strategies from the ERIC.


Serves as a preliminary aid to strategy consideration by providing a broad array of candidate strategies that best address barriers.



Waltz, T.J., Powell, B.J., Fernández, M.E. *et al.* Choosing implementation strategies to address contextual barriers: diversity in recommendations and future directions. *Implementation Sci* 14, 42 (2019). <u>https://doi.org/10.1186/s13012-019-0892-4</u>


# Research Question & Aims


- How do actual implementation strategies compare with those recommended by an expert opinion-based tool?
- Convergent parallel mixed-methods study to improve guidelineconcordant cirrhosis care in the Veterans Health Administration (VHA) aimed to:
  - Identify pre-implementation CFIR barriers to liver cancer surveillance
  - Generate 20 recommended strategies using the CFIR-ERIC matching tool
  - Collect data over two consecutive years on actual use and effectiveness of 73 strategies
  - Compare actual vs. recommended strategy use
  - Compare actual vs. expected barriers by reverse application of the CFIR-ERIC matching tool



# Study Design

#### Convergent parallel mixed-methods





# Methods: Data Collection

Focus Groups: CFIR-based, semi-structured, n=18

- Participants (n=197) represented 95 sites across all 18 VISNs
- Gastroenterology/hepatology, infectious disease, pharmacy, and operations
- Surveys: Tailored ERIC survey across VHA in two consecutive years

# Methods: Data Analysis

#### > CFIR-ERIC Matching Tool

- Inputs = barriers defined by focus groups
- Output= top 20 highest "recommended" strategies, based on cumulative percentage endorsement

#### Cirrhosis Care Indicator

- > HCC surveillance data aggregated to the VA site level
- Point-biserial tests assessed correlations

# Results: Focus Group

#### **Barriers**

- Intervention Characteristics
  - Adaptability
  - Complexity

#### Outer Setting

- External policy
- Patient needs and resources

#### Inner Setting

- Relative priority
- Readiness
- Leadership engagement
- Available resources
- Structural characteristics
- Compatibility

#### **Facilitators**

#### • Implementation Process

- Infrastructure and communication
- Data tools for reflecting and evaluating

#### Characteristics of Individuals

• Self-efficacy due to prior success

Using the Excel matching tool, add 10 barrier inputs to get strategy recommendations.

	А	В	C					
2	Select All	INTERVENTION CHARACTERISTICS						
3	0	Intervention Source	Stakeholders have a negative perception of the innovation because of the entity that developed it and/or where it was developed.					
4	0	Evidence Strength & Quality	Stakeholders have a negative perception of the quality and validity of evidence supporting the intervention.					
5	0	Relative advantage	Stakeholders do not see the advantage of implementing the innovation compared to an alternative solution or keeping things the same.					
6	1	Adaptability	Stakeholders do not believe that the innovation can be sufficiently adapted, tailored, or re-invented to meet local needs.					
7	0	Trialability	Stakeholders believe they cannot test the innovation on a smaller scale within the organization or undo implementation if needed.					
8	1	Complexity	Stakeholders believe that the innovation is complex based on their perception of duration, scope, radicalness, disruptiveness, centrality, and/or intricacy and number of steps needed to implement.					
9	0	Design Quality and Packaging	Stakeholders believe the innovation is poor quality based on the way it is bundled, presented, and/or assembled.					
10	0	Cost	Stakeholders believe the innovation costs and/or the costs to implement (including investment, supply, and opportunity costs) are too high.					
11		OUTER SETTING						
12	1	Patient Needs & Resources	Patient needs, including barriers and facilitators to meet those needs, are not accurately known and/or this information is not a high priority for the organization.					
13	0	Cosmopolitanism	The organization is not well networked with external organizations.					
14	0	Peer Pressure	There is little pressure to implement the innovation because other key peer or competing organizations have not already implemented the innovation nor is the organization doing this in a bid for a competitive edge.					
	1	External Policy & Incentives	External policies, regulations (governmental or other central entity), mandates, recommendations or guidelines, pay-for-performance, collaborative, or public or benchmark reporting do not exist or they undermine efforts to implement the					

### Results: Top 20 Recommended Strategies

1. Assess for readiness and identify barriers and facilitators
2. Conduct local consensus discussions
3. Promote adaptability
4. Conduct local needs assessment
5. Identify and prepare champions
6. Build a coalition
7. Alter incentive/allowance structures
8. Capture and share local knowledge
9. Tailor strategies
10. Conduct cyclical small tests of change
11. Involve executive boards
12. Involve patients and family members
13. Facilitation
14. Develop a formal implementation blueprint
15. Create a learning collaborative
16. Obtain and use patients and family feedback
17. Access new funding
18. Inform local opinion leaders
19. Identify early adopters
20. Fund and contract for clinical innovation

# Results: Comparing Recommended vs. Actual Strategies

Top 20 Recommended ERIC strategies	Actual st	trategy use		Strategy significance
	FY18	FY19	Тор	
1. Assess for readiness and identify barriers and facilitators	25%	13%		19
2. Conduct local consensus discussions	38%	23%	18	19
3. Promote adaptability	43%	42%	Both	Both
4. Conduct local needs assessment	24%	20%		19
5. Identify and prepare champions	44%	36%	Both	19
6. Build a coalition	40%	20%	18	19
7. Alter incentive/allowance structures	3%	3%		
8. Capture and share local knowledge	41%	26%	18	18
9. Tailor strategies	44%	40%	Both	Both
10. Conduct cyclical small tests of change	17%	16%		Both
11. Involve executive boards	19%	3%		
12. Involve patients and family members	25%	28%	19	19
13. Facilitation	14%	18%		
14. Develop a formal implementation blueprint	19%	12%		
15. Create a learning collaborative	30%	21%		18
16. Obtain and use patients and family feedback	11%	5%		18
17. Access new funding	24%	17%		
18. Inform local opinion leaders	30%	21%		18
19. Identify early adopters	14%	8%		
20. Fund and contract for clinical innovation	21%	15%		18

"Top" column denotes in which fiscal year the strategy was most frequently used. "Strategy significance" column denotes in which year the strategy was significantly associated with HCC surveillance

## Results: Recommended vs. Actual Strategy USE

Of the top 20 "recommended" strategies, 7 were a top strategy used in each or both years:

#### Other most USED strategies

- -Data warehousing (dashboard)
- -Change physical structure and equipment
- -Change the record system
- -Use data experts
- -Network weaving
- -facilitate the relay of data to clinicians
- -Provide expert consultation
- -Educational materials/meetings

FY18	FY19			
Build a coalition	Involve patients and family members			
Conduct local consensus discussions				
Capture and share local knowledge				
Promote adaptability				
Tailor strategies				
Identify and prepare champions				

# Results: Recommended strategies associated with cancer screening

- 11 of the top 20 most recommended (70%) were associated with cancer screening (vs. 48% (35/73) of total strategies) \*=most used
- \*\*=most used BUT not in the year


#### Other most USED strategies

- -Data warehousing (dashboard)\*
- -Change physical structure and equipment
- -Change the record system\*
- -Use data experts\*
- -Network weaving\*
- -facilitate the relay of data to clinicians
- -Provide expert consultation\*
- -Educational materials/meetings

FY18	FY19				
Capture and share local knowledge*	Involve patients and family members*				
Create a learning collaborative	Identify and prepare champions**				
Obtain and use family and patient feedback	Conduct local consensus discussions**				
Inform local opinion leaders	Build a coalition**				
Fund and contract for the clinical innovation	Assess for readiness and identify barriers and facilitators				
Promote adaptability*					
Tailor strategies*					
Conduct cyclical tests of change					
	20				

### Timing

- 6 strategies were associated with HCC screening uniquely in FY19 (the year after barriers were assessed)
- 5 of the 6 were the highest "recommended" strategies based on barriers
- Barriers reported in FY18 were successfully addressed by recommended strategies in FY19





### Results: Reverse Mapping Actual Strategies and Expected Barriers

Entered 25 strategies most used strategies

- 5 were unique to FY18, 6 to FY19, and 14 overlapped both years, totaling 25 strategies
- Reverse mapping found 15 barriers
  - 7 (47%) had been previously reported by focus groups
  - Multiple strategies addressed the same expected barrier

Results: Reverse Mapping

Most used actual ERIC strategies (wording tailored to cirrhosis care)		strategy	Strategy significance	Expected CFIR barrier (per CFIR-ERIC Matching Tool)	Actual barrier
	FY18	FY19			
Use data warehousing techniques	73%	75%	Both	Reflecting & evaluating	
Change physical structure and equipment	67%	50%		Available resources	а
Change the record systems	60%	53%	19	Reflecting & evaluating	
Use data experts to manage cirrhosis data	51%	37%	18	Reflecting & evaluating	
• Build on existing high-quality working relationships and networks to promote information sharing and problem-solving related to implementing cirrhosis care	49%	-	Both	Networks & communications	
Facilitate the relay of clinical data to providers	49%	40%		Reflecting & evaluating	
Tailor strategies to deliver cirrhosis care to address specific barriers in your center	44%	40%	Both	Compatibility	а
Identify and prepare champions	44%	36%	19	Champions	
• Identify the ways cirrhosis care can be tailored to meet local needs and while still maintaining the core components of evidence-based care	43%	42%	Both	Adaptability	а
Provide ongoing consultation with one or more cirrhosis treatment experts	43%	32%	Both	Self-efficacy	
Distribute educational materials	43%	35%	18	Access to knowledge & information	
Intentionally examine the efforts to promote cirrhosis care	43%	38%	18	Executing	
Share the knowledge gained from quality improvement efforts with other sites outside your medical center	41%	-	18	Adaptability	а
Conduct educational meetings	41%	44%		Access to knowledge & information	
Build a local coalition/team to address challenges	40%	-	19	Cosmopolitanism	
Develop reminder systems for clinicians	40%	36%	19	Leadership engagement	а
Conduct local consensus discussions	38%	-	19	Relative priority	а
Provide ongoing training in cirrhosis care	38%	33%	18	Self-efficacy	
Provide clinical supervision around evidence-based cirrhosis care	37%	34%	18	Access to knowledge & information	
Intervene with patients to promote uptake of and adherence to cirrhosis care	33%	-	Both	Patient engagement	
Revise professional roles	-	35%		Structural characteristics	а
Have an expert in cirrhosis care meet with providers to educate them	-	32%		Evidence strength & quality	
Engage in efforts to prepare patients to be active participants in cirrhosis care	-	29%	Both	Patient engagement	
Involve patients and family members	-	28%	19	Patient needs & resources	а
Create new clinical teams	-	28%		Networks & communications 23	

Barriers addressed by most popular strategies but not identified in focus groups




# Discussion

CFIR-ERIC Matching Tool identified strategies more likely to be associated with cancer screening

- Reverse application of matching tool based on actual strategies used demonstrated that:
  - Barriers shifted over time, reflecting context and local needs
  - Strategy selection spanning multiple years must attend to progression of context

#### > Future:

- Further study of barrier combinations and relative intensity
- Revision of the CFIR-ERIC Matching Tool using updated empirical data
- How to leverage a single strategy to address multiple barriers (Waltz et al.)
- How to prescribe combos, or bundles



### Thank you!

 Vera Yakovchenko, Matt Chinman, Carolyn Lamorte, Sandra Gibson, Monica Merante, Brittney Neely

- The ERIC and CFIR teams!
- Thank you to HHRC NGHP, OMHSP, and the amazing providers in VA!
- Shari.rogal@va.gov